Oriana Papin-Zoghbi is the CEO and Co-Founder of AOA Dx, a biotech company focused on early-stage ovarian cancer detection.  She has a proven record of creating market entry strategies and product launches in new markets, including launching nationwide HPV screening in East Africa and novel diagnostics in maternal-fetal medicine. Oriana has received numerous awards in entrepreneurship, including the Massachusetts Life Sciences Center MassNextGen Award and The Wave Summit’s Emerging Women Founder in Bio Award.

AOA Dx Inc is a Y Combinator and VC-backed biotech company focused on early-stage cancer detection. AOA partnered with a leading oncology researcher at McGill University to develop the first early-stage ovarian cancer liquid biopsy diagnostic test. The co-founders have worked together for the last decade at two previous startups in the women’s health space, both resulting in successful exits upon commercialization. Ovarian cancer is the deadliest gynaecological disease because there is no accurate testing method and its symptoms are continuously mistaken for benign conditions, making it incredibly difficult to diagnose the disease in the early stages. Early diagnosis will reduce patient mortality and deliver cost savings to payers.